Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | patient whose ΔHb is less than 1.0g/dL on the day of 7th administration |
|
| 2 | Experimental | patient whose ΔHb is 1.0g/dL or above on the day of 7th administration |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| recombinant human erythropoietin | Drug | 3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| The increase in Hb concentration | Day 28th or later |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in QOL scores | 84 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yoshiharu Ishikura | Chugai Pharmaceutical | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| recombinant human erythropoietin | Drug | 36000IU(s.c.)/week for 12 weeks |
|